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When animal viruses cross the species barrier to infect humans, few 
attain the capacity for human-to-human transmission. Only this latter 
framework that large epidemics with severe disease outcome ensue. This was 
evident in the 2003 severe acute respiratory syndrome (SARS) and ebola 
epidemic in West Africa in 2014-15. While the spread of these viruses in 
humans is aided by low or even non-existent herd immunity, the outcome of 
infection is thought to be driven by the lack of adaptation in humans. 
Consequently, it is possible that the rate of asymptomatic infection of newly 
emerged viruses is low.  Indeed, this was the observation for infection with 
SARS coronavirus in 2003 where no asymptomatic infection was detected in 
seroprevalence studies in healthcare workers here in Singapore. Hence, case 
isolation, tracing of contacts with cases and quarantine were effective in 
stemming the spread of this virus in Singapore.   
 
In 2009, a new strain of H1N1 emerged in the Americas and quickly 
swept across the world and Singapore was not spared.  The Ministry of Health 
of Singapore initially adopted the same strategy of case isolation, contact 
tracing and quarantine to contain the spread of the H1N1 virus in Singapore.  
Unlike SARS, however, this strategy did not produce the desired results and 
the strategy was abandoned after the first several weeks of the epidemic in 
Singapore.  One possibility for the failure of the “SARS strategy” to contain 
H1N1 is the difference in the asymptomatic infection rate, where individuals 
without overt clinical symptoms could continue to transmit the virus in the 
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community.  Hence, the first part of the thesis sought to determine the 
proportion of asymptomatic infection with pandemic influenza A H1N1 2009.  
Results from this thesis shows, through a prospective cohort study, that there 
is high proportion (79.6%) of asymptomatic infection for the newly emerged 
pandemic influenza A H1N1 2009. The high proportion of asymptomatic 
infection of the pandemic influenza A H1N1 2009 could explain the 
inefficiency of isolation and quarantine interventions to contain the spread of 
pandemic influenza A H1N1 2009.  
 
For the second part of this thesis, the prevalence and temporal trends of 
respiratory pathogens in adults that presented with acute febrile illness at 
primary healthcare centers was investigated. Such epidemiological data could 
guide the implementation of vaccination programs which is especially relevant 
in tropical countries. This is especially pertinent as epidemic influenza activity 
is less seasonal in the tropics than in temperate countries.  Data in this thesis 
shows that there is a strong bi-annual seasonal pattern for influenza A.  
Furthermore, the peak in the middle of the year (April – June) is higher than 
the peak at the end or beginning of each year (November - February). The 
findings in this thesis provide new perspective on prevention of influenza and 
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1.1 Influenza  
 
Influenza, is a respiratory tract infection caused by influenza viruses. 
All influenza viruses (A, B and C) are RNA viruses belonging to the family of 
Orthomyxoviridae and are differentiated by the antigenic properties of their 
nucleoprotein and matrix proteins. Influenza A can be further subdivided into 
distinct subtype based on the genetic and antigenic properties of their two 
surface glycoproteins haemagglutinin (HA) and neuradminidase (NA), 
responsible for virus binding to relevant host and releasing of newly formed 
infectious virions, respectively. To date, 16 HA subtypes (H1- H16) and 9 NA 
subtypes (N1 – N9) have been identified and all of these subtypes have been 
detected in wild aquatic birds throughout the world (Webster et al. 1992, 
Wright et al. 2013) while new strains of H17N10 and H18N11 subtypes have 
been recently identified in bats (Tong et al. 2012, Tong et al. 2013). Generally, 
influenza A viruses are found in migratory birds (shorebirds and waterfowls) 
which are considered their natural reservoirs (Wright et al. 2013). They have 
also been known to circulate in many other animal hosts including poultry, 
humans, pigs, horses and dogs (Wright et al. 2013).  
 
The antigenic properties of HA allow the classification of influenza A 
viruses into two major groups, group 1 and 2, which are further classified into 
five clades and 16 subtypes (figure 1A). Bat-derived H17 and H18 (each 
marked with a star) belong to group 1. Influenza NAs could also be grouped 
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into two groups and the bat-derived N10 and N11 (each marked with a star) do 
not belong to either group (figure 1B). They are NA homologs or could be 
called NA-like molecules and are proposed to be categorized as influenza A-
like group 3 (Wu et al. 2014). At present only viruses of H1, H2 and H3 HA 
subtypes and N1 and N2 NA subtypes have caused pandemics and annual 




Figure 1 Phylogenetic trees of the (A) hemagglutinin (HA) and (B) 
neuraminidase (NA) genes of all known influenza A virus subtypes including 












1.2 Genome, structure and life cycle of influenza A virus 
 
The genome of influenza A virus consists of eight single-stranded, 
negative-sense viral RNA (vRNA) segments that encodes at least 11 
functional proteins needed for infection, replication and evasion of antiviral 
response (Medina and Garcia-Sastre 2011, Wright et al. 2013). The virus 
possesses a host cell derived lipid-bilayer membrane which contains the 
hemagglutinin (HA), the neuraminidase (NA), and traversed by the matrix 
protein 2 (M2) proton channel (Wright et al. 2013). Each ribonucleoprotein 
(RNP) complex interacts with the matrix protein 1 (M1), which lies just 
beneath the lipid bilayer, and assist in viral assembly. The M1 and M2 proteins 
are encoded by the M gene segment, while HA and NA are encoded by their 
respective HA and NA gene segments. Within the virus particle, each of the 
eight RNA segments form a viral ribonucleoprotein (RNP) complex with the 
viral RNA (vRNA) wrapping around the nucleoprotein (NP) and then bound to 
the trimeric viral polymerase complex that comprises Polymerase basic 1 
(PB1), Polymerase basic 2 (PB2) and Polymerase acid (PA) proteins (figure 2) 






Figure 2 Genomic components of influenza A virus. The influenza A virus 
genome consists of eight segmented single-stranded RNA that encodes at least 
11 proteins. The matrix protein M1 and the ion channel M2 are encoded by the 
M gene segment. The receptor-binding HA protein, the sialic acid receptor 
cleavage NA protein, the nucleoprotein (NP) and the components of the RNA-
dependent RNA polymerase complex (PB1, PB2 and PA) are all expressed 
from their respective genome segments. The nuclear export protein (NEP, also 
known as NS2) and the host antiviral response antagonist non-structural 
protein 1 (NS1) are encoded by the NS segment. (Medina and Garcia-Sastre 
2011)  A newly identified N40 protein with unknown function is expressed 
from PB1 segment (Wise et al. 2009) and some viruses expresses the pro-
apoptotic PB1-F2 protein is also encoded by the PB1 segment. Figure adapted 
from (Medina and Garcia-Sastre 2011)  
 
Influenza virus infections are initiated by the binding of viral HA on 
host cells sialic acid-containing receptors on the target cell surface, triggering 
receptor-mediated endocytosis and subsequent fusion within the low-pH 
environment of the endosome (figure 3) (Medina and Garcia-Sastre 2011, 
Neumann et al. 2009, Wright et al. 2013). The HA proteins of human 
influenza viruses preferentially bind to sialic acid linked to galactose by an -
α2,6-linkage (SAα2,6 Gal) (Ito and Kawaoka 2000), which is the predominant 
receptor expressed on epithelial cells in the upper respiratory tract of humans 
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(de Graaf and Fouchier 2014, Matrosovich et al. 2004, Nicholls et al. 2007, 
Shinya et al. 2006), while avian influenza viruses preferentially bind to sialic 
acid-α2,3-galactose (SAα2,3 Gal) (Ito and Kawaoka 2000), which is 
predominantly expressed in the intestinal tract of waterfrowl where avian 
influenza replicate efficiently and spread via fecal-oral route to other birds (de 
Graaf and Fouchier 2014, Ito and Kawaoka 2000, Nicholls et al. 2008). These 
differences in HA receptor specificity are a critical determinant in influenza 
host range (de Graaf and Fouchier 2014).  
 
The HA proteins undergoes an irreversible conformational change that 
expose the HA peptide (fusion peptide) that is responsible for the fusion 
between the viral envelope and the endosomal membrane. Oligomerized M2 
proteins form an ion channel that result in proton influx that acidifies the 
interior of the virion, which is necessary for viral uncoating of the RNP 
complexes that contain the viral genome. Acidification of the endosome also 
triggers the pH-dependent fusion step that is mediated by HA and results in the 
cytoplasmic release of the vRNP complexes (figure 3). These translocate to 
the nucleus, where they function as templates for genome transcription and 
replication. The RNA-dependent RNA polymerase transcribes and replicates 
the negative-sense viral RNA ((–) vRNA), to give rise to mRNA that are 
exported to the cytoplasm for translation by the host cell translation 
machinery; and complementary positive-sense RNA ((+) cRNA) which 
function as a template for genomic (vRNA) replication.  
 
After their translation, viral polymerase subunit proteins and 
nucleoproteins that are needed in replication and transcription are imported 
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into the nucleus via their nuclear localization signals (Matsuoka et al. 2013, 
Resa-Infante et al. 2008), and progeny vRNPs are then exported to the 
cytoplasm for packaging, assisted by M1 (Bui et al. 2000, Chase et al. 2011, 
Martin and Helenius 1991) and nuclear export proteins (NEP) (Cao et al. 
2012, Neumann et al. 2000, O'Neill et al. 1998). Assembly and budding of 
virions occurs at the cell surface in lipid raft microdomains. Viral HA, NA and 
M2 are transported by the trans-Golgi secretory pathway, and the mature 
proteins arrive at the plasma membrane, where M1 assists in the formation of 
virus particles. Release from the host cells is mediated by the neuraminidase 
activity of NA which cleaves the HA from sialic acid receptors (Medina and 











Figure 3 Replication cycle of influenza A viruses. Infection is initiated when 
viral HA binds to either SAα2,6Gal or SAα2,3Gal bearing receptors on host 
cell surface and enter the cells via receptor-mediated endocytosis. Cleavage of 
HA expose the HA peptide that is responsible for the fusion between the viral 
envelope and the endosomal membrane. Proton influx from M2 ion channel 
results in acidification of the inside of the virion, that is required for proper 
uncoating of the RNP complexes that contain the viral genome. vRNP then 
translocate to the nucleus, where the RNA-dependent RNA polymerase 
transcribes and replicates the negative-sense viral RNA ((–) vRNA), giving 
rise to complementary positive-sense RNA ((+) cRNA), which it uses as a 
template to generate more vRNA and the viral mRNAs, which are exported to 
the cytoplasm for translation. Viral proteins that are needed in replication and 
transcription are translocated back to the nucleus, and progeny RNPs are then 
exported to the cytoplasm for packaging, assisted by M1 and NEP. Viral HA, 
NA and M2 are transported by the trans-Golgi secretory pathway, and the 
mature proteins arrive at the plasma membrane, where M1 assists in the 
formation of virus particles (Medina and Garcia-Sastre 2011). Budding then 
occurs, and release from the host cells is mediated by the neuraminidase 
activity of NA, which destroys the SA of the cellular and viral glycoproteins 
that would otherwise retain the new virions at the cell surface (Medina and 







1.3 Threat of influenza epidemics 
 
1.3.1 Seasonal influenza 
 
Human viral influenza is probably one of the most important 
respiratory infectious diseases of mankind that can cause recurrent seasonal 
epidemics and occasional global pandemics with devastating levels of 
morbidity and mortality. Seasonal influenza epidemics are responsible for 
more than 250 000 death annually with significant infection rates worldwide, 
affecting people of all age groups and have substantial health and economic 
burdens (WHO 2014a). Singapore is also affected by influenza epidemics. 
20% of Singapore population is estimated to have clinical influenza annually 
(Ng et al. 2002), with a mortality rate of approximately 14.8 per 100,000 
person-years comparable to those in the temperate countries (Chow et al. 
2006, Lee et al. 2007). The burden of influenza in Singapore is high. In the 
study by Ng et al (2002), the authors estimated 630 000 cases of influenza 
infection resulting in 520 000 sick visits and 315 000 days of work absentees, 
annually.   
 
There is clear seasonal variation in the occurrence of influenza in the 
temperate regions, with peak in cold winter months, while influenza occurs 
year-round in the tropical regions. Influenza can seriously affect all 
populations, causing mild to severe illness which can result in hospitalization 
or death. Those with the highest risk of complications occurring among 
children younger than two years, adults aged 65 years or older, pregnant 
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women and people of any age with certain medical conditions such as chronic 
heart, lung, kidney, liver, blood or metabolic diseases (such as diabetes), or 
weakened immune systems (WHO 2014a). Influenza virus causes a highly 
contagious respiratory disease that can spread from person to person via 
inhalation of virus via aerosol droplets generated during coughing and 
sneezing. Influenza causes a wide spectrum of clinical presentations including 
symptoms like sudden onset of fever, headache, cough (usually dry), sore 
throat, myalgia, nasal congestion, generalized muscular aches, weakness, loss 
of appetite and sneezing.  
 
Seasonal influenza viruses continuously undergo antigenic changes in 
the viral HA and, to a lesser extent, in the viral NA via antigenic drift and 
these changes allow the influenza viruses to escape from the host immunity. 
Antigenic drift occurs through mutations generated by the error-prone viral 
polymerase during viral replication, which generates antigenic variants within 
the haemagglutinin (HA) and neuraminidase (NA) proteins that enables the 
virus to evade immune recognition. Thus seasonal influenza viruses evolve 
continuously, and people can be infected multiple times throughout their lives. 
Because of this, influenza vaccines are reviewed frequently (currently 
biannually) and updated periodically so as to be effective against newly 
evolving seasonal influenza viruses that are likely to circulate in the following 
influenza season (WHO 2014a).  
 
Seasonal influenza A of subtypes H1N1 and H3N2 have been co-
circulating in humans since 1977. In addition, there are two types of influenza 
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B viruses that are also circulating, the Victoria and Yamagata lineages, named 
after the areas where they were first identified. Both H1N 1 and H3N2 
subtypes have distinct evolutionary dynamics, with H1N1 drifting at a slower 
rate (Rambaut et al. 2008) and they each undergo frequent reassortment 
among lineages within their subtype (Holmes et al. 2005, Nelson et al. 2006, 
Nelson et al. 2008). Reassortment event occurs when co-infection of two or 
more influenza viruses (same or different subtypes) occurs in a single host 
facilitating the exchange of gene segments between viruses. Hence, multiple 
lineages of both subtypes persist and co-circulate together contributing to the 
overall genetic pool that is present in a season (Holmes et al. 2005). Large-
scale analysis of H1N1 and H3N2 virus sequences has led to the hypothesis of 
a “source-sink” model of viral evolution, in which a “source” population in the 
tropical regions, likely East or Southeast Asia, seeds annual outbreak in 
temperate regions of the northern and southern hemispheres (Rambaut et al. 
2008, Russell et al. 2008). In contrast, an alternative equal contact model has 
been proposed that there are no restrictions for viral migration between 
tropical and temperate regions (Bahl et al. 2011, Bedford et al. 2010).  
 
1.3.2 Pandemic influenza 
 
Influenza A virus was the causative agent of four major pandemics; the 
1918 H1N1 Spanish flu, 1957 H2N2 Asian flu, 1968 H3N2 Hong Kong flu 
(figure 4), and the 2009 swine-origin pandemic flu (2009 pH1N1), as well as 
of a relatively milder pandemic, the 1977 Russian flu where H1N1 reappeared 
(Cox and Subbarao 2000, Kobasa et al. 2004, Peiris et al. 2009). The 1918 
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Spanish influenza pandemic was the most devastating in documented history, 
infecting hundreds of millions and claiming more than 50 million lives 
worldwide (Johnson and Mueller 2002). The 1918 pandemic was unusual in 
its disproportionally high mortality rate in young adults aged 15-34 years 




Figure 4 Influenza pandemics. The 1918 Spanish influenza was probably 
caused by the transmission of an avian influenza virus to humans. In 1957, the 
introduction of avian virus H2 HA, N2 NA and PB1 genes into human 
populations resulted in the Asian influenza. Similarly, the introduction of 
avian virus H3 HA and PB1 genes into human populations led to the Hong 
Kong influenza in 1968. In 1977, H1N1 viruses reappeared, which closely 
resembled strains that had been circulating in the mid-1950s. Figure taken 
from (Neumann et al. 2009). 
 
Genetic reassortment (figure 5) of viral gene segments in host cells co-
infected with two distinct influenza A viruses can generate antigenic shift in 
HA and NA proteins and this may result in pandemic strain to which a large 
proportion of the world’s population may be susceptible (Tscherne and 
Garcia-Sastre 2011). It is believed that most human pandemic viruses arose in 
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this manner as demonstrated in 1957 H2N2 Asian flu and 1968 H3N2 Hong 
Kong flu (Kilbourne 2006, Neumann et al. 2009, Nicholson et al. 2003, 
Taubenberger et al. 2005) where HA and NA of avian virus origin emerged in 
the human population while direct transfer from avian influenza reservoir 




Figure 5 Reassortment. Reassortment can occur in cells that are co-infected 
with two different influenza A viruses and can theoretically result in 256 
different genotypes (28, i.e., the two parental genomes and 254 new 
genotypes). Reassortment is a major mechanism for the generation of 
pandemic influenza viruses, as demonstrated in 1957 (Asian influenza) and 
1968   (Hong Kong influenza) (Wright et al. 2007). Figure adapted from 
(Wright et al. 2007).  
 
The descendants of H1N1 virus from the 1918 pandemic circulated 
until 1957, when they are replaced with an avian/human reassortant of H2N2 
subtype that caused a new pandemic (the Asian flu). These H2N2 viruses 
continued in the human population until 1968, when they are replaced by 
another avian/human reassortant virus, first isolated in Hong Kong, that 
retained the N2 NA from the circulating H2N2 viruses, but acquired an H3 
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HA, as well as PB1 segment, of avian origin (the Hong Kong flu) (Scholtissek 
et al. 1978). In 1977, H1N1 viruses reappeared, which closely resembled 
strains that had been circulating in the mid-1950s, prior to the H2N2 outbreak 
(Nakajima et al. 1978). The reemergence of this virus did not cause a full-scale 
pandemic, likely because of pre-existing immunity to viruses of this subtype in 
individuals born before 1957. Since 1977, viruses of the H1N1 and H3N2 
subtypes have been cocirculating in humans (Rambaut et al. 2008).  
 
The emergence of the pandemic H1N1 in 2009 demonstrates that 
influenza virus evolution can occur in animals (in this case, swine) and re-
emerge as a strain that is antigenically distinct from the endemic H1N1 
introduced in 1977 (Garten et al. 2009, Smith et al. 2009). Genetic and 
evolutionary analysis revealed that this virus contains a complex set of genes 
that were originated from viruses that infect birds, humans and pigs (Smith et 
al. 2009) and that it was likely to be derived from viruses that had been 
circulating undetected in swine populations for approximately one decade 
(Smith et al. 2009). Influenza viruses similar to the 1918 pandemic H1N1 
virus became established in domestic pigs between 1918 and 1920 and this 
lineage is referred to as the classical swine lineage. In 1979, a distinct Eurasian 
‘avian-like’ H1N1 virus emerged in European pigs and has since co-circulated 
with the classical swine H1N1 viruses. In the late 1990s, reassortment between 
human H3N2, North American avian, and classical swine viruses resulted in 
triple reassortant H3N2 and H1N2 swine viruses that have since circulated in 
North American pig populations. The swine-origin pandemic H1N1 probably 
results from recent North American H3N2 and H1N2 swine viruses (that is, 
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avian/human/swine “triple” reassortant viruses) with Eurasian avian-like swine 
virus (figure 6) (Novel Swine-Origin Influenza et al. 2009). Thus, the 2009 
pandemic H1N1 virus is composed of PB2 and PA segments from North 
American avian viruses, the PB1 segment of the human H3N2 viruses, 
haemagglutinin (H1 subtype), nucleoprotein (NP) and NS segments derived 
from classical swine H1N1 viruses, and the neuraminidase (N1 subtype) and 




Figure 6 Genesis of pandemic 2009 H1N1 viruses. The swine-origin 
pandemic H1N1 probably results from recent North American H3N2 and 
H1N2 swine viruses (that is, avian/human/swine “triple” reassortant viruses) 
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with Eurasian avian-like swine virus. The NA and M genes were derived from 
a Eurasian avian-like swine virus. The remaining six genes were derived from 
triple resssortant swine viruses that possessed genes originating from classical 
H1N1 swine, North American avian and human H3N2 viruses (Neumann and 
Kawaoka 2011, Peiris et al. 2009). Figure adapted from (Neumann et al. 2009) 
 
The emergence of the pandemic influenza A/H1N1 in April 2009 has 
drastically changed the circulation dynamics of the previous seasonal 
influenza virus strains. The 2009 pandemic H1N1 virus have largely replaced 
seasonal H1N1 viruses. Thus, World Health Organization (WHO) 
recommended seasonal trivalent vaccine formulation to replace seasonal 
H1N1 viruses with pandemic H1N1 (2009) strain in 2010 (Southern 
Hemisphere) and 2010/2011 (Northern Hemisphere) vaccine formulation and 
will therefore be protected against all the expected seasonal influenza viruses, 
including seasonal H3N2 and influenza B. Clinically, infection with the 
pandemic 2009 H1N1 appears to be indistinguishable in severity and 
symptoms from seasonal H1N1 or H3N2 influenza, with some exceptions 
(Dawood et al. 2009). First, gastrointestinal symptoms including diarrhea and 
vomiting have been reported with pandemic 2009 H1N1 infection, which are 
unusual with seasonal influenza infection (Dawood et al. 2009). Next, the 
younger population (less than 35 years of age) are more vulnerable to 
pandemic 2009 H1N1 infection than the old (more than 65 years of age), 
seasonal influenza infection tend to affect elderly (Dawood et al. 2009). The 
sera of elderly individuals has been shown to contain cross-reactive antibodies 
to the 2009 H1N1 virus (Hancock et al. 2009, Itoh et al. 2009), suggestive of 





1.3.3 Zoonotic influenza 
 
In the past decades various influenza A viruses have occasionally 
crossed the animal-human host species barrier and infected humans who come 
in close contact to infected poultry.  Avian influenza A virus strains such as 
H5N1, H6N1, H7N3, H7N7, H7N9, and H10N8 have been discovered to 
directly infect humans and cause severe respiratory disease (de Jong et al. 
1997, Fouchier et al. 2004, Gao et al. 2013, Hirst et al. 2004, Kageyama et al. 
2013, Qi et al. 2014, Tweed et al. 2004, Wei et al. 2013). Human influenza 
infections caused by swine-origin influenza A viruses have also been 
identified (CDC 2014a, Lindstrom et al. 2012) and these viruses are called 
“variant viruses” and denoted with a letter “v”. Although some of these strains 
caused lethal infections, the lack of sustained person-to-person transmission 
has been the major factor that prevented these viruses from causing new 
pandemics (Pascua and Choi 2014).  
 
The initial outbreak of the highly pathogenic avian influenza (HPAI) 
virus of H5N1 subtype in poultry in Hong Kong was soon followed by reports 
of human infections with high fatality rate. Since then, various clusters of 
antigenically divergent HPAI H5 lineages have spread throughout Asia into 
Europe and Africa, causing outbreaks in poultry populations and an increasing 
number of human zoonotic infections and fatalities (Sonnberg et al. 2013, 
WHO 2014b). Influenza A H5N1 virus appears to induce a more systemic 
disease with high viral titers in the respiratory tract and detectable viral 
antigen or RNA in blood, cerebrospinal fluid as well as internal organs 
17 
 
(Abdel-Ghafar et al. 2008, de Jong et al. 2006, Wang et al. 2008). As of 
October 2nd, 2014, World Health Organization (WHO) has been notified of 
668 human cases of infection with H5N1 in 16 countries since 1997 wherein 
about 60% were fatal (393 deaths) (WHO 2014c).  
 
The recently emerged avian influenza of H7N9 subtype has also 
caused sporadic infections in humans since its first detection in China, in 
March 2013 (Gao et al. 2013). Since then there were 451 confirmed cases of 
H7N9 human infection reported to WHO (436 from China) spreading to 
neighbouring Hong Kong (10 cases), Taiwan (4 cases) and Malaysia (1 case) 
(Jeyanthi 2014, Lin et al. 2014, Lo et al. 2013, To et al. 2014). All cases in 
Hong Kong, Taiwan, and Malaysia were either imported from or had a travel 
history to the Chinese provinces (Jeyanthi 2014, Lin et al. 2014, Lo et al. 
2013, To et al. 2014). Out of the 451 reported H7N9 cases, 165 have 
succumbed to the disease, which amounts to over 36% fatality rate (WHO 
2014d).  The source of infection is assumed to be infected poultry or 
contaminated environments. Many of the human cases have reported visiting 
markets where live poultry were sold (Xu et al. 2013, Yu et al. 2014). The 
findings of H7N9 seropositive poultry workers indicate subclinical human 
infections (Yang et al. 2014) and others have identified H7N9 positive 
individuals experiencing mild to moderate influenza virus symptoms that 
recovered quickly (Li et al. 2014, Yang et al. 2013, Yu et al. 2013) suggesting 
the presence of unidentified, mild cases of human H7N9 infections. The 
internal genes of the H7N9 virus belong to the same genetic lineage as the 
internal genes of the H5N1 virus, of which both are derived from H9N2 
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viruses (Guan et al. 1999, Lam et al. 2013). Phylogenetic analyses revealed 
that the novel H7N9 viruses likely emerged via four reassortment events 
between H9N2 viruses and avian‐origin viruses of subtype H7 and N9 (Lam et 
al. 2013, Liu et al. 2013). The imported cases in Hong Kong, Taiwan and 
Malaysia are the only reports outside China, indicating that it has not yet gone 
global dissemination.  
 
Beginning in August 2011, human infection with influenza H3N2v was 
detected across United States. As of October 2014, 351 cases have been 
confirmed (CDC 2014a, CDC 2015). None of these cases were fatal and most 
were mild. Genetic sequencing of the recent H3N2v isolates revealed that the 
virus has acquired the nucleoprotein (NP) and matrix (M) gene from the 2009 
influenza A H1N1 pandemic virus, whereas previous isolates from human 
cases only had the M gene from the pandemic virus (CDC 2014b-d, Shu et al. 
2012). Many of the human cases occurred after direct or indirect exposure 
with infected pig at agricultural fairs (Wong et al. 2011, Bowman et al. 2012). 
There is no evidence of effective person-to-person transmission with this virus 
and severity of illness is similar to that seen with seasonal influenza (CDC 
2012a). Limited serologic studies indicate that children aged less than 10 years 
lack cross-protective antibiotics to H3N2v whereas some older children and 
adults do have cross-reactive antibodies to the virus (CDC 2012b). Human 
cases of H1N2v infections have also been reported in the United States with 
the pandemic M gene from the 2009 H1N1 virus (CDC 2012c). These cases 




Fortunately, there are no indications that these zoonotic influenza 
viruses have the capacity to spread efficiently from human to human. 
However, two independent studies have simultaneously demonstrated that few 
changes in the HPAI H5N1 viral genome could confer airborne transmission 
between mammals (Herfst et al. 2012, Imai et al. 2012). And some reports 
have shown that H7N9 viruses already are capable of limited transmission in 
humans (Qi et al. 2013) and in mammalian infection models (Belser et al. 
2013, Watanabe et al. 2013, Zhang et al. 2013, Zhu et al. 2013), suggesting 
that they possess pandemic potential. With the inherent capacity of influenza 
A viruses to evolve and adapt, it is only a matter of time before these avian 
influenza viruses are capable of sustaining person-to-person transmissions. 
The impact of these newly emerged viruses is usually greater as these animal 
viruses have not been adapted in humans.  
 
Despite the wide host range of influenza A viruses, their transmission 
from avian to mammalian species is rare due to host range restrictions. Avian 
and human influenza viruses typically have a different sialic acid (SA)‐binding 
preference. Avian influenza viruses recognize specific α2,3-linked sialic acid 
receptors of susceptible cells lining the intestinal gut of avian hosts (Ito et al. 
1998), whereas human influenza virus have preference for α2,6-linked sialic 
acid receptors, which are present on the epithelium of the human upper 
respiratory tract (e.g., nasal passages and trachea) (Shinya et al. 2006).  
Humans also possess α2,3-linked sialic acid receptors which are found in the 
lower respiratory cells (e.g., lungs) (Matrosovich et al. 2004, Shinya et al. 
2006). Therefore it is not surprising that extensive or prolonged exposure to 
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affected poultry increases the chances of interspecies transmission. The 
presence of both α2,3- and α2,6-linked sialic acid receptors on swine 
respiratory tract epithelial cells make pigs susceptible to both avian and human 
influenza viruses (Ito et al. 1998). Hence, infection of pigs with avian 
influenza A viruses could facilitate adaptation to mammalian host via 
accumulation of adaptive mutations. Specific modifications in the HA protein 
through adaptation can shifts receptor recognition, which can in turn switches 
binding preferences to receptors that are expressed by mammalian hosts. 
Moreover, many have proposed that pig may serve as ‘mixing vessels’ for 
genetic reassortment of human and avian viruses (Webster et al. 1992), and 
their subsequent transmission to humans. The presence of a multi-basic 
cleavage site within HA correlates well with pathogenicity of HPAI viruses in 
poultry (Steinhauer 1999). Cleavage of the HA precursor, HA0, into HA1 and 
HA2 exposes the amino terminus of HA2 containing fusion peptide, allowing 
for virus envelop fusion with host endosomal membrane. The accumulation of 
polybasic residues on this cleavage site, typically seen among highly 
pathogenic avian influenza (HPAI) H5 and H7 viruses could make HA readily 
cleaved by ubiquitous host proteases thus promoting systemic infection 
(Stieneke-Grober et al. 1992).  
 
1.4 Current vaccines and their limitation  
 
Annual influenza vaccination remains the most effective 
countermeasure for preventing influenza infection and its complications. 
Influenza vaccines have been available for over 50 years and have provided 
effective protection when vaccine strains matches the circulating influenza 
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virus strains. Seasonal influenza viruses continuously undergo antigenic 
changes in the viral HA via antigenic drift or shift. Because of this, the 
composition of the influenza vaccine needs to be reviewed frequently and 
adapted to these changes regularly so as to be effective against newly evolving 
seasonal influenza viruses that are likely to circulate in the following influenza 
season. The monitoring of these changes is done by the Global Influenza 
Surveillance and Response System (GISRS) which is a global public health 
laboratory network coordinated by World Health Organization (WHO) and are 
currently comprises of six WHO Collaborating Centers for Influenza, four 
WHO Essential Regulatory Laboratories (ERL) and 142 institutions as 
National Influenza Centers in 112 WHO Member States and 12 WHO H5 
Reference Laboratories that monitors the evolution of influenza viruses 
globally. WHO reviewed and make recommendation biannually for the strains 
to be included in the trivalent influenza vaccine for the coming influenza 
season, once in February for the forthcoming winter in the Northern 
Hemisphere and in September for the next influenza season in the Southern 
Hemisphere (WHO 2014a). These recommendations are used to guide national 
public health authorities and pharmaceutical companies for developing and 
production of influenza vaccines for the next influenza season. Table 1 listed 
the seasonal influenza vaccine composition recommended by WHO for both 
Northern and Southern Hemispheres from 2010. The seasonal influenza 
vaccines are trivalent, consisting of three strains; two strains of influenza A 
viruses (H3N2 and H1N1) and one strain of influenza B that are most likely to 
circulate in the coming season. Starting with the 2013-2014 northern 
hemisphere influenza season, quadrivalent vaccine composition has been 
22 
 
recommended with a second influenza B virus in addition to the viruses in the 
conventional trivalent vaccines to provide wider protection against influenza B 















































Table 1 WHO recommendation on the composition for Seasonal vaccine for 
Southern and Northern Hemisphere  
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There are two influenza vaccines currently in the market, the injectable 
trivalent inactivated influenza vaccines (TIV) and intranasally administered 
live-attenuated influenza vaccine (LAIV). Traditionally, influenza vaccines are 
produced using embryonated chicken eggs and this production process takes 
approximately five to six months for the first supplies of approved vaccine to 
be available. Because of this long production process, the manufacturing has 
to begin in advance of a flu season. If there were significant antigenic drift 
occurring during this lengthy production period to the final vaccine product, 
this can result in a mismatch between the circulating strains and the vaccine 
strains which can reduce the effectiveness of the vaccine (Carrat and Flahault 
2007). Therefore, it is a challenge to keep up to the changes of the viral HA 
proteins as well as the speed of vaccine production. In addition, the situation is 
further complicated by the disproportionate correlation between genetic 
change and antigenicity (Smith et al. 2004), making it difficult to predict the 
effectiveness of the vaccine formulation.  
 
Antiviral drugs for influenza are available for prophylaxis and 
treatment for severe complications and death but antiviral resistance is a 
continuing problem (van der Vries et al. 2013). There are two classes of drugs 
that are currently available, namely the M2 ion channel blockers adamantanes 
(amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir and 
zanamivir; as well as peramivir and laninamivir licensed in several countries). 
Resistance of adamantanes conferred by mutation S31N in the viral M2 
protein are found in some influenza A subtypes, including seasonal H3N2 
(Bright et al. 2005, Deyde et al. 2007), seasonal H1N1(Cheng et al. 2009, 
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Saito et al. 2008), pandemic H1N1 (Giria et al. 2012, Zaraket et al. 2011) and 
avian H5N1 viruses (Cheung et al. 2006, McKimm-Breschkin et al. 2007). 
The other two drugs, oseltamivir and zanamivir, has also shown extensive 
resistance conferred by H275Y mutations in the NA gene of the virus (Dharan 
et al. 2009, Hurt et al. 2009, Meijer et al. 2009). These highlight the need for 
developing new anti-viral strategies with novel mechanisms of action and with 
reduced drug resistance potential. WHO also monitors antiviral susceptibility 
among circulating influenza viruses. Currently, WHO recommends 
neuraminidase inhibitors as the first-line treatment for people requiring 
antiviral therapy, as the currently circulating influenza viruses are resistant to 
the adamantanes. 
 
1.5 Influenza seasonality 
 
There are clear seasonal variations in the occurrence of influenza in the 
temperate regions of the world, with peak incidence in the winter months 
(Nicholson et al. 2003) while influenza occurs year-round in the tropical 
regions. Influenza in the northern hemisphere temperate usually peaks 
between December and February while in the southern hemisphere, the peaks 
occur between June and July. In contrast, seasonality is less defined in tropical 
regions. Observations are not always consistent, with some studies but not 
others showing seasonal variation. Most countries like Indonesia (Beckett et 
al. 2004, Kosasih et al. 2013), Myanmar (Hasegawa et al. 2006) and Vietnam 
(Nguyen et al. 2007) reported peaks associated with rainy seasons (Hampson 
1999). In Singapore, influenza activities are detected throughout the year, with 
26 
 
peaks in influenza A (April - July and November -January) coinciding with 
winter in the northern and southern hemisphere (Chew et al. 1998, 
Doraisingham et al. 1988, Shek and Lee 2003). Distinct seasonality was also 
not observed in studies reported from South Brazil (Straliotto et al. 2002), 
Hongkong (Chan et al. 1999), or Taiwan (Tsai et al. 2001). 
 
1.6 Viral respiratory infections 
 
Besides influenza, other viruses also cause acute respiratory tract 
infections in humans and collectively, they form are the most common 
infectious disease experienced by people of all ages worldwide (Monto 2002). 
It has considerable impact on health and causing significant morbidity and 
mortality throughout the world particularly in children who may experience 
multiple infections per year (Feigin RD 2004). A wide range of viruses have 
been detected to cause respiratory tract infections, including respiratory 
syncytial virus (RSV), influenza A and B viruses, parainfluenza viruses 
(PIVs), adenovirus (AdV), rhinovirus (HRV) and coronavirus type OC43 and 
229E (Brittain-Long et al. , Broor et al. 2007, Druce et al. 2005, Hatipoglu et 
al. 2011, Khor et al. , Kwofie et al. 2012, Minosse et al. 2008, Ren et al. 2009, 
Yu et al. 2012).  
 
Traditionally, the diagnosis of these infections relied on the isolation 
and identification of the viral agent by cell culture or detection of viral 
antigens by direct immunofluorescent assay (DFA) (Ginocchio 2007, 
Loeffelholz and Chonmaitree 2010). Over the last decade, progress in 
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molecular technologies has greatly improved the detection of viral respiratory 
pathogens. Newly discovered viruses include human metapneumovirus 
(HMPV) (van den Hoogen et al. 2001), coronaviruses NL63 (HCoV-NL63) 
(van der Hoek et al. 2004) and HKU1 (HCoV-HKU1) (Woo et al. 2005), 
human bocavirus (HBoV) (Allander et al. 2005), novel strains of 
polyomaviruses (WU and KI) (Allander et al. 2007, Gaynor et al. 2007) and 
the recent Middle East respiratory syndrome-coronavirus (MERS-CoV) (Zaki 
et al. 2012). However, there are about 30 – 50% of respiratory infections 
remain undiagnosed etiologically (Brittain-Long et al. , Broor et al. 2007, 
Druce et al. 2005, Hatipoglu et al. 2011, Khor et al. , Kwofie et al. 2012, 
Minosse et al. 2008, Ren et al. 2009, Yu et al.) and this suggest that there 
might be novel agents that are yet to be identified.  
 
Respiratory viruses generally spread via contact or inhalation of 
infectious aerosolized droplets generated by coughs or sneezes. Etiological 
diagnosis of respiratory infection requires laboratory confirmation as clinical 
presentation of these respiratory viruses is mostly non-specific. The prevention 
and control of respiratory viral infections are limited by the availability of 
antiviral for treatment or prophylaxis and there are no approved vaccines 
(except for influenza and adenovirus) despite considerable efforts in these 
areas. Adenovirus vaccine contains live adenovirus type 4 and 7 and therefore 
will only prevent illness caused by these two virus types (FDA 2014). And 
although there is trivalent vaccine available for influenza (H3N2, H1N1 and 
B), the latest composition requires matching to current circulating strains as 
antigenic changes is common and requiring new vaccines to be made bi-
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annually before the targeted season in the winter months in northern and 
southern hemispheres. Currently, there are no licensed antiviral for most of the 
major causes of respiratory infections, and most treatments are usually 
symptomatic and supportive.  
 
1.7 Emerging respiratory viruses 
 
Emerging viral respiratory infectious disease is a major worldwide 
threat to global health security (Morens et al. 2008). Over the past decade, 
several novel viruses causing respiratory tract infections in humans with 
epidemic and pandemic potential have emerged in different parts of the world, 
most of which emerged from interactions between people and animals (Fauci 
and Morens 2012). In 2003, the World Health Organization (WHO) issued a 
global alert for an unknown emerging disease that was later known as Severe 
Acute Respiratory Syndrome (SARS) caused by a novel coronavirus (SARS-
CoV) (WHO 2003a) rapidly spreading worldwide and causing more than 8000 
cases and 800 deaths in more than 30 countries before coming to a halt by July 
2003 mainly owing to isolation and quarantine (WHO 2003b). Since then, 
several other viral respiratory pathogens (table 2) have emerged including 
avian influenza viruses of subtype H5N1 (Subbarao et al. 1998), H7N9 (Gao 
et al. 2013), and H10N8 (Kelvin K. W. To et al. 2014), Human 
metapneumovirus (van den Hoogen et al. 2001), bocavirus (Allander et al. 
2005), the swine-origin influenza A H1N1 (WHO 2009), human adenovirus-
14 (Kajon et al. 2010), as well as the Middle East respiratory syndrome-
coronavirus (MERS-CoV) (Zaki et al. 2012). Soon after the discovery of 
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SARS-CoV, other coronaviruses such as the coronavirus NL63 (van der Hoek 
et al. 2004) and coronavirus HKU1 (Woo et al. 2005) were also identified.  
 
Table 2 Emerging respiratory viruses 
 
Type of Virus Year Region Reference 
Influenza A H5N1 1997 Hong Kong (Subbarao et al. 1998) 
Influenza A H9N2 1999 Hong Kong (Peiris et al. 1999) 
Human metapneumovirus 2001 Netherlands 
(van den Hoogen et al. 
2001) 
SARS coronavirus 2003 Hong Kong 
(Ksiazek et al. 2003, 
Peiris et al. 2003) 
Human coronavirus – 
NL63 
2004 Netherlands 
(van der Hoek et al. 
2004) 
Influenza A H7N7 2004 Netherlands (Koopmans et al. 2004) 
Human coronavirus – 
HKU1 
2005 Hong Kong (Woo et al. 2005) 
Influenza A, H1 triple 
reassortant 
2005 USA 
(Newman et al. 2008, 
Shinde et al. 2009) 
Bocavirus 2005 Sweden (Allander et al. 2005) 
Influenza A H1N1 pdm09 2009 Mexico (WHO 2009) 
Adenovirus 14 2010 USA (Kajon et al. 2010) 
MERS - coronavirus 2012 Saudi Arabia (Zaki et al. 2012) 
Influenza A H7N9 2013 China (Gao et al. 2013) 
Influenza A H10N8 2013 China 
(Kelvin K. W. To et al. 
2014) 
Taken from (Al-Tawfiq et al. 2014) with modification 
 
Middle East respiratory syndrome coronavirus (MERS-CoV) was first 
detected in Saudi Arabia in 2012 (Zaki et al. 2012), approximately ten years 
after SARS-HCoV emerged in 2003 in Guangdong Province, China. Globally, 
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World Health Organization has been notified of 909 laboratory-confirmed 
cases of infection with MERS-CoV, with 331 related deaths (mortality was 
about 38%)  as of November, 2014 (WHO 2014e). Most patients had 
respiratory disease with a range of clinical manifestations from mild, 
asymptomatic cases to severe multi-organ failure and death.  Overall, all 
confirmed cases were originated from or had a history of travel to the Middle 
East, with few secondary cases (WHO 2014e). The mode of transmission of 
MERS-CoV is still poorly understood, which makes it difficult to implement 
invention and preventive measure. MERS-CoV was predicted to be readily 
transmitted through an oral–faecal route and also possibly via respiratory 
secretions (Goh et al. 2013) or could be through respiratory droplets or direct 
or indirect contact (Assiri et al. 2013). The reservoir for MERS-CoV is 
currently unknown. Studies in Oman and Egypt have shown that dromedary 
camels (Camelus dromedarius) have neutralizing antibodies to MERS-CoV 
(Reusken et al. 2013) which led to the speculation that dromedary camels may 
be the intermediate host of MERS-CoV. Genomic sequences of MERS-CoV 
isolates from two patients and from their infected camels were almost 
identical, suggesting camel-to-human transmission  (Azhar et al. 2014, 
Memish et al. 2014). These studies suggest that camels are a likely primary 
source of the MERS-CoV that is infecting humans (Azhar et al. 2014, Memish 
et al. 2014).  
 
Human coronavirus – NL63 (HCoV–NL63), a member of the group I 
coronavirus, was first detected in 2004 in a child with bronchiolitis in The 
Netherlands (van der Hoek et al. 2004), whilst human coronavirus – HKU1 
31 
 
(HCoV–HKU1) ), a member of the group II coronavirus, was detected in 2005 
in an adult with chronic pulmonary disease in Hong Kong (Woo et al. 2005). 
HCoV–NL63 has been identified as an agent of laryngotracheitis (croup) 
(Stang et al. 2006). Common respiratory symptoms accompanying HCoV–
HKU1 infection are rhinorrhoea, fever, coughing, wheezing, and disease 
manifestations include bronchiolitis and pneumonia (Lau et al. 2006, Sloots et 
al. 2006). HCoV–NL63 and –HKU1 infections are generally not life 
threatening but can cause more severe clinical symptoms in young children, 
elderly and immune-compromised persons (Holmes 2001, McIntosh et al. 
1974, van Elden et al. 2004). HCoV–NL63 has been successfully cultured in 
monkey epithelial cell lines (Schildgen et al. 2006) but not for HCoV–HKU1. 
The difficulty in isolating some of the newly identified viruses explain why 
they have not previously been detected.  
 
Human metapneumovirus (HMPV) is a new human respiratory 
pathogen that was first isolated in 2001 in the Netherlands by cell culture from 
nasopharyngeal aspirates collected from 28 hospitalized children and infants 
with acute respiratory tract infection (ARTI) during a 20-year period (van den 
Hoogen et al. 2001). Two major genotypes of HMPV, designated A and B are 
recognized, each with two subtypes (A1 and A2; B1 and B2) (Biacchesi et al. 
2003, Mackay et al. 2004).  Several reports have shown that HMPV is a 
common cause of lower respiratory tract infection in children, and is second to 
respiratory syncytial virus (RSV) infection as cause of bronchiolitis in early 
childhood (Boivin et al. 2003, Chano et al. 2005, Freymouth et al. 2003, Kahn 
2006, Laham et al. 2004, van den Hoogen et al. 2003). HMPV infection in 
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adults usually present with mild common-cold like respiratory symptoms such 
as rhinorrhoea, cough and sore throat (Falsey et al. 2003) and are more severe 
in patients with underlying medical conditions (Boivin et al. 2002, Falsey et al. 
2003, Hamelin et al. 2005). HMPV has a global distribution (Al-Sonboli et al. 
2005, Boivin et al. 2004, Cuevas et al. 2003, Dollner et al. 2004, Ebihara et al. 
2004, Esper et al. 2003, Freymouth et al. 2003, Gray et al. 2006, Kim and Lee 
2005, Ludewick et al. 2005). In temperate regions, HMPV circulates 
predominately in the late winter/spring period (from December through 
March), and the peak activity often overlaps with or follow the peaks of 
respiratory syncytial virus (RSV) (Boivin et al. 2003, Bouscambert-Duchamp 
et al. 2005, Chano et al. 2005, Esper et al. 2004, Kaida et al. 2006, König et al. 
2004, Maggi et al. 2003). HMPV grows poorly in cell culture and is restricted 
to a limited number of cell lines (van den Hoogen et al. 2001) which could 
explain why the virus was not identified until recently. Currently, molecular 
method by polymerase chain reaction is the most common method used to 
detect HMPV targeting N and L genes for detection of HMPV strains of both 
genotypes (Côté et al. 2003).  
 
Human bocavirus (HBoV) was initially identified by Tobias Allander 
in 2005 (Allander et al. 2005) in 17 respiratory samples from children 
suffering from respiratory infections of unknown etiology. Based on sequence 
analyses of these 17 isolates, HBoV was grouped into the family Parvoviridae, 
subfamily Parvovirinae, and genus Bocavirus. To date, four subtypes, named 
HBoV1–4, have been identified and can be found worldwide. HBoV1 is 
associated with respiratory disease and is more frequently detected in young 
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children (<2 years of age) than in older children or adults, while HBoV2 to 4 
are more frequently associated with gastrointestinal infections and symptoms 
(Kapoor et al. 2010, Schildgen et al. 2008, Schildgen et al. 2012, Volz et al. 
2007). Clinical manifestations have ranged from mild upper respiratory tract 
infections to severe pneumonia. Currently, there is no cell culture system or 
animal model established for HBoV and there is no documented cases of 
human-to-human transmission of HBoV. Due to the lack of an animal model 
and a versatile cell culture system, diagnosis of HBoV infection is exclusively 
based on molecular detection methods.  
 
1.8 Research questions  
 
1.8.1 Proportion of asymptomatic infection 
 
During the last decade, Singapore has been struck by two major 
pandemic; in 2003, Singapore experienced the outbreak of Severe acute 
respiratory syndrome (SARS) and in 2009, the influenza A H1N1 pandemic. 
The World Health Organization (WHO) issued a global alert (WHO 2003a) 
for SARS that was rapidly spreading worldwide and causing more than 8000 
cases and 800 deaths in more than 30 countries before coming to a halt by July 
2003 (WHO 2003a). Containment of the SARS outbreak in Singapore 
involved the implementation of various stringent control measures, such as 
early identification and isolation of the suspected and probable cases in a 
designated hospital, contact tracing, quarantine of all the contacts that are 
exposed to the SARS, school closures as well as temperature checks at the 
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borders, in schools and in hospital (Gopalakrishna et al. 2004, Tan 2006). 
Among the several control measures, early identification and isolation of the 
cases with management of their contacts has been shown to be highly effective 
in interrupting transmission (Tan 2006).  
 
The pandemic 2009 Influenza A/H1N1, on the other hand, presented a 
different set of challenges altogether. Using the experience from SARS, 
Singapore quickly implemented similar control measures to contain the 
outbreak (Cutter et al. 2010). Public health policy during the containment 
phase includes isolation of infected case-patients and quarantine of exposed 
persons to prevent local transmission. However, about three weeks after the 
first case was reported, community transmissions, with no links to the first 
case, broke out at an alarming rate. Singapore had to modify its strategy, with 
the focus shifting from containing the spread of the virus to mitigating the 
effects of the outbreak. Controls measures were slowly stepped down. 
Thermal scanning at checkpoints, home quarantine orders and contact tracing 
were eventually discontinued and shifted to caring for patients with severe 
illness and conditions that put them at risk for complications (Cutter et al. 
2010, Mukherjee et al. 2010).  
 
The effectiveness of the control measures is partly influenced by the 
transmission characteristics of the virus. Early identification and isolation of 
cases successfully interrupted SARS transmission probably because SARS has 
a long serial interval between successive cases in a chain of transmission is 
about 8 to 10 days and infectivity peaks 2 weeks after illness onset. 
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Furthermore, there is no subclinical and or asymptomatic infection (Chow et 
al. 2004, Ho et al. 2004), which means that all the infected cases develop 
symptoms. Hence early identification of infected cases allows isolation to be 
implemented before virus shedding starts. All these factors favor isolation and 
quarantine interventions that were essential in controlling SARS. Influenza’s 
shorter serial interval between successive cases (2 to 4 days) and earlier peak 
infectivity, together with the presence of mild cases and the possibility of high 
proportion of asymptomatic infection, suggest that these measures would be 
considerably less successful than they were for SARS.  
 
Newly emerged viruses would typically cause higher rates of infection 
and mortality among humans as pre-existing immunity does not exist at the 
time of their emergence. Thus we would expect asymptomatic infection of 
newly emerged viruses to be low or none (as in the case for SARS) as they 
have not been adapted to humans. The 2009 influenza pandemic offers us an 
opportunity to test this hypothesis. It is plausible to postulate that the 
asymptomatic infection rates in newly emerged viruses (the pandemic 
influenza A H1N1) are lower than seasonal influenza strains. The aim of this 
study is thus to determine the proportion of asymptomatic infection of 
influenza A H1N1. We will take advantage of the volunteers enrolled for the 
chloroquine for influenza prevention (CHIP) clinical trial that was conducted 
between November 2009 and February 2010.The original trial showed no 
efficacy of chloroquine for influenza prevention, and therefore the total 
number of 1482 individuals that were enrolled in this study and provided 
paired serum samples were included in the analysis.  Subjects were asked to 
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take nasal swabs if they experienced influenza-like symptoms during the 
course of study, and tested for influenza and other respiratory viruses by 
polymerase chain reaction (PCR). Paired sera will be used to determine the 
rates of seroconversion to influenza A/H1N1 2009, seasonal influenza 
A/H3N2 and influenza B using haemagglutination inhibition (HAI) test.  The 
primary outcome was seroconversion to influenza with 4-fold rise in antibody 
titers.  This data will then be compared to the diary of symptoms experienced 
by the volunteers over the 12-week period.  The findings of this study have 
important implication on public health strategies to control future influenza 
pandemics. 
 
1.8.2 Temporal trends of respiratory viruses in Singapore 
 
In the second part of this thesis, the common etiologies of viral 
respiratory infection in Singapore were determined and the temporal trends of 
these viruses explored. Such epidemiological data could guide the 
implementation of vaccination programs which is especially relevant in 
tropical countries since epidemic influenza activity is less seasonal than those 
experienced in temperate countries (Chew et al. 1998, Shek and Lee 2003)  
and the choice of vaccination with the northern or southern hemisphere 
vaccine formulation depends on when peak transmission occurs. Because 
influenza viruses are constantly changing, it is advisable to get vaccinated so 
as to get protected against the circulating strains, and the World Health 
Organization (WHO) make recommendation for the vaccine composition 
twice a year for the upcoming influenza season in the northern and southern 
37 
 
hemisphere. For tropical countries influenza seasonality is less defined than in 
temperate countries, therefore the time of vaccination as well as the choice of 
vaccine formulation depend on when peak transmission of influenza occurs for 
that country. Furthermore, the clinical presentation of viral infections of the 
respiratory tract is mostly non-specific and there are no rapid point-of-care 
diagnostics that can differentiate all the common etiologies reliably. Hence, 
diagnosis and case management strategies are guided by information on the 
prevalence of these etiological agents.  
 
Thus, to determine the prevalence of respiratory viruses in Singapore 
and their temporal trends, we took advantage of adult patients with acute 
febrile illness that were enrolled in a longitudinal dengue study in Singapore 
where laboratory-confirmed dengue cases formed the minority of patients with 
acute febrile illness presenting at a primary health care clinic (Low et al. 
2006). Knowledge on the prevalence and seasonal patterns of the various 
respiratory viruses could facilitate early detection of unusual patterns that 
could herald the emergence of novel respiratory pathogens. It could also serve 
to guide public health measures to reduce the overall burden of acute 









2. MATERIALS AND METHODS 
 
2.1 Asymptomatic influenza study  
 
We took advantage of a prospective cohort study that recruited healthy 
adult volunteers to test for the efficacy of chloroquine as a prophylaxis to 
prevent acute influenza (Paton et al. 2011). This chloroquine for influenza 
prevention (CHIP) trial was a randomized, double-blind, placebo-controlled 
trial conducted in Singapore during the 2009 H1N1 influenza A pandemic.  
The inclusion and exclusion criteria of the CHIP trial is summarized in table 3. 
Participants are healthy at the point of recruitment and were recruited between 
November 2009 and February 2010 through a study website that provided 
information about the trial and for registration for screening (Paton et al. 
2011). Participants were male or female healthy volunteers aged 18 to 65 
years. Those who have had influenza vaccination within the past three months 
and or acute clinical influenza at screening were excluded. Participants were 
randomly assigned to placebo or chloroquine group. The trial showed no 
efficacy of chloroquine for influenza prevention (Paton et al. 2011) and 
therefore I was able to combine data from both chloroquine and placebo group 












Table 3 The Chloroquine for Influenza Prevention (CHIP) trial inclusion and 
exclusion criteria  
 
Inclusion criteria 
Healthy male or female 
18 – 65 years old 
Exclusion criteria 
History of psoriasis 
Porphyria cutanea tarda 
Epilepsy 
Myasthenia gavis 
Myopathy of any cause 
Cardiac arrhythmias 
Retinal disease 
Serious hepatic or renal disease 
Known glucose-6-phosphate dehydrogenase deficiency  
Current use of medication with known serious hepatotoxic effects or known 
interaction with chloroquine  
Severe depression 
Influenza vaccination within the past 3 months 




Baseline demographics and clinical history was recorded. Blood was 
drawn at baseline and at week 12 during follow-up. During the course of 12 
weeks, participants were asked to take nasal swab samples if any influenza-
like symptoms associated with fever, runny nose or cough arises. Participants 
were given nasal swabs pack containing 2 swabs and RNA-stabilizing media 
(PrimeStore, Longhorn Vaccines and Diagnostics, San Antonio, USA). After 
use, swabs were sealed and kept in the refrigerator until they returned at week 
12 visit. In addition, participants called the trial hotline and a replacement 
pack will be send to them by post. Participants were also required to complete 
weekly and daily diaries on a secure, password protected trial website for any 
influenza-like symptoms and continued this diary until symptoms resolved.  
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This diary consisted of a checklist of symptoms that participants graded as 
none, mild or moderate to severe. Participants are also required to report other 
symptoms - body temperature (a standard digital thermometer was provided), 
and absence from work or school caused by the sickness and adherence to the 
study intervention (Paton et al. 2011).  
 
All paired serum samples were tested by haemagglutination inhibition 
assays (HAI) to detect for infection with influenza A H1N1, H3N2 or 
influenza B. Nasal swabs were tested by polymerase chain reaction (PCR) for 
influenza virus and a panel of respiratory viruses, including rhinovirus, 
enterovirus, coronavirus, human metapneumovirus, parainfluenza virus 1, 2 
and 3, respiratory syncytial virus and adenovirus. All HAI and PCR tests were 
done by me.  
  
2.1.1 Haemagglutination Inhibition (HAI) Test 
 
All paired serum samples were tested by haemagglutination inhibition 
test (HAI) to detect infection with influenza A/H1N1 2009, A/H3N2 or 
influenza B according to World Health Organization (WHO) standard 
protocols (WHO 2011). Serum samples were pre-treated with receptor 
destroying enzyme (RDE [II], Deka Seiken Co Ltd, Tokyo, Japan) at 37°C for 
16-18 hours, before enzyme inactivation in a 56°C water bath for 30 minutes. 
Physiological saline was added to the sera with a final dilution of 1:10. To 
remove non-specific agglutinins from the serum samples, the serum was 
adsorbed with red blood cells (RBC). One volume of guinea pig packed RBC 
was added to 20 volumes of RDE-treated serum and incubated at 4°C for one 
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hour with mixing at intervals to resuspend the cells. The RBCs were 
centrifuged down at 5000 rpm for 5 minutes and carefully removed the 
adsorbed serum without disturbing the packed RBCs. 25 µl of standardized 
HA antigen of 4 HA units (influenza A/H1N1 2009, or H3N2 or influenza B) 
was incubated with an equal volume of RDE-treated serum that was titrated in 
two-fold dilution in phosphate buffer solution from 1:10 to 1:640 and 
incubated for 15 minutes at room temperature. Influenza A/H1N1 2009, 
A/H3N2 and influenza B virus was previously isolated from another study. 50 
µl of 0.75% guinea pig RBCs was added to each well and read after 1 hour at 
room temperature. Influenza viruses and control sera were isolated and drawn 
from local patients presenting with acute febrile illness to primary healthcare 
clinics in 2009. Titers were expressed as the reciprocal of the highest serum 
dilution that effectively inhibits agglutination of red blood cells by a specific 
influenza strain. Individual seroconversion was indicated by a four-fold or 
greater rise in titers between the paired samples.  
 
2.1.2 PCR on nasal swabs 
 
The nasal swabs collected were stored in RNA-stabilizing media 
(PrimeStore, Longhorn Vaccines and Diagnostics, San Antonio, USA) and 
were tested by real-time polymerase chain reaction (PCR) for influenza 
viruses and a panel of other respiratory viruses, including rhinovirus, 
enterovirus, coronavirus, human metapneumovirus, parainfluenza virus 1, 2 
and 3, respiratory syncytial virus and adenovirus. Viral nucleic acid was 
extracted from nasal swabs using QIAamp Viral RNA Mini Kit (Qiagen, 
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Valencia, CA, USA) according to the manufacturer’s protocol and was either 
used immediately or stored at -80ºC until use. cDNA was synthesized using  
SuperScript™ III First-Strand Synthesis System (Invitrogen™, Carlsbad, CA, 
USA). Briefly, 8 µl of nucleic extract was mixed with 1 µl of random hexamer 
and 1 µl of 10 nM dNTP mix in a final volume of 10 µl. This was incubated at 
65ºC for 5 minutes to denature RNA secondary structures on Applied 
Biosystems™ (Foster City, CA, USA) Veriti 96 Well Thermal Cycler and was 
placed on ice for 5 min. 2 µl of 10x RT buffer, 4 µl of 25mM MgCl2, 2 µl of 
0.1M DTT, 1 µl of RNase OUT (40 U/ µl) and 1 µl of SuperScript™ III RT 
enzyme (200 U/ µl) was added and incubated at 25 ◦C for 10 min for 
annealing, 50 ◦C for 50 min for cDNA synthesis and then 85 ◦C for 5 min to 
terminate the reactions using the Applied Biosystems™ (Foster City, CA, 
USA) Veriti 96 Well Thermal Cycler. The cDNA product was then chilled on 
ice for 5 min, and 1 µl of RNase H was added and incubated at 37 ◦C for 20 
min to degrade viral and carrier RNA. cDNA products were stored at −80 ◦C.  
 
Primers used to detect specific viruses were taken either from the 
literature or designed in-house. The sequence information of the primers for 
used to detect for 11 respiratory viruses is shown in table 4, with their 
respective target gene and product size. All reactions were set up as single-
plex assays. PCR positive controls were clinical isolates from another study or 
bought from ATCC. Real time-PCR was done using LightCycler480 SYBR 
Green I Master kit (Roche, USA) according to manufacturers’ instructions and 
run on LightCycler480 (Roche, USA) in a total volume of 20 µl containing 10 
µl of 2x Master Mix, 2.8 µl of 25mM MgCl2, 1 µl of each forward and reverse 
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primer (10 µM), 3.2 µl of Rnase free water and 2 µl of cDNA. Cycling 
conditions were 95°C for 5 mins, followed by 40 cycles of 95°C for 10 secs, 
55 °C for 5 secs and 72°C for 10 secs, with melting curve analysis after the 
PCR amplification to verify that the correct product was amplified by 
examining its specific melting temperature (Tm). PCR was done using 
Platinum® Taq DNA polymerase (Invitrogen, ) and was carried out in 50 µl 
reaction mix containing 5 µl 5X PCR buffer, 2 µl 10 mM dNTP mix, 2 µl 50 
mM MgCl2, 1 µl  of forward and reverse primer (10 µM each), 0.25 µl of 
Platinum® Taq DNA polymerase, 36.75 µl of RNase free water and 2 µl of 
cDNA. Thermocycling was performed on Applied Biosystems™ (Foster City, 
CA, USA) Veriti 96 Well Thermal Cycler, under the following cycling 
conditions: initial denaturation at 94°C for 5 min, followed by 40 cycles at 
94°C for 10 sec, 55°C for 10 sec and 72°C for 10 sec, with final extension at 
72°C for 3 mins.  PCR products were loaded on to 2% agarose gel containing 



















sequence (5’ – 3’) 
Reverse primer 




































et al. 2004) 




















et al. 2004) 












et al. 2004) 












et al. 2004) 




149 PCR (Watzinger 




































251 PCR In-house 
design by 
ChaoNan 
HMPV, Human Metapneumovirus; PIV, parainfluenza ; RSV, respiratory syncytial virus ; RV, 
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2.1.3 Statistical analysis 
 
We compared differences in asymptomatic rates between newly 
emerged influenza A/H1N1 2009 and seasonal influenza A/H3N2 and 
influenza B using Fisher’s exact test . P < 0.05 and < 0.01 was considered 
statistically significant and highly significant. 
 
2.2 Temporal trends of respiratory viruses 
 
We took advantage of a longitudinal study that systematically enrolls 
patients that present with acute febrile illness at selected primary healthcare 
centers to test for respiratory pathogens. This Early DENgue (EDEN) infection 
and outcome study is a collaborative longitudinal study to investigate 
epidemiological, clinical, viral and host-specific features of early dengue-
infected adults, in an effort to identify new early markers for prognostication 
(Low et al. 2006). While the primary objective of this study was dengue, it 
became apparent to us early on that most of the patients enrolled were negative 
for dengue (Low et al. 2006). We hence included the collection of 
nasopharyngeal (NP) swabs from these patients since January 2008. The study 
protocol was approved by the National Healthcare Group domain specific 
review board (DSRB B/05/013). Briefly, adult patients (age ≥ 18 years) 
presenting with a fever or a history of fever (temperature ≥ 37.8oC) of less 
than 72 hours from illness onset were enrolled upon informed written consent 
as previously described (Low et al. 2011).  Clinical and epidemiological 
information were collected using a standardized questionnaire.  Venous blood 
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and NP swabs were obtained at enrolment as well as a follow-up visit 2-3 days 
later and tested for dengue virus and a panel of respiratory viruses, 
respectively.  The findings for dengue virus have been reported previously 
(Low et al. 2011, Low et al. 2006).  
 
2.2.1 DFA and Virus isolation in R-MixTM shell vials 
 
All respiratory samples collected were tested for viral pathogens by 
direct immunofluorescence assay (DFA) and virus isolation using R-MixTM 
cells in shell vials (Diagnostic Hybrids Inc., Athens, Ohio) according to the 
manufacturer’s instructions. The D3 Ultra DFA Respiratory Virus Screening 
and ID Kit (Diagnostic Hybrids Inc., Athens, Ohio) was used to detect for 
influenza A and B, respiratory syncytial virus, human metapneumovirus, 
adenovirus, and parainfluenza 1, 2 and 3 in both DFA as well as shell vial 
cultures. Briefly, The NP swabs were vortexed in phosphate-buffered saline 
(PBS) to release the virus and virus-infected cells, and centrifuged at 1,500xg 
for 5 min. The supernatant was aliquot into cryotubes and kept in -80oC until 
ready to inoculate into R-mixTM shell vials for virus isolation.  The cell pellet 
was resuspended in the remaining PBS (approximately 0.6 ml to 0.8 ml) and 
for each specimen, smears were prepared on slides by cytocentrifugation using 
a cytospin apparatus and fixed in 80% acetone. The slides were stained with 
D3 Ultra DFA Respiratory Virus Screening and ID Kit (Diagnostic Hybrids 





Virus isolation was done using R-mixTM shell vials according to the 
manufacturer’s instructions. The R-mixTM shell vials contained human lung 
carcinoma cells (A549) and mink lung (Mv1Lu) cells grown on coverslips in 
vials and were obtained from Diagnostic Hybrids, Inc. (Athens, Ohio). The 
culture medium was removed prior to inoculation of approximately 0.2ml of 
nasopharyngeal swabs collected from the patients into each of the 2 R-mixTM 
shell vials. The vials were centrifuged at 700xg for 1 hour and refed with the 
refeed medium. The vials were incubated at 37°C in 5% CO2 for 24 hours. 
Cover slips were fixed with acetone and stained with D3 Ultra DFA 
Respiratory Virus Screening and ID Kit (Diagnostic Hybrids Inc., Athens, 
Ohio) for detection of seven respiratory viruses, including influenza A and B 
viruses, parainfluenza viruses type 1, 2, and 3, adenovirus and respiratory 
syncytial virus after 24 hours post-infection. The coverslips were examined 
under fluorescence microscope for the presence of virus. 
 
2.2.2 Nucleic acid extraction and Luminex xTAG® RVP assay 
 
We also conducted a sub-analysis of all samples collected in 2010 that 
were negative by either DFA or virus isolation using a nucleic acid multiplex 
xTAG® Respiratory Virus Panel (RVP) FAST assay (Luminex Molecular 
Diagnostics, Toronto). Viral nucleic acid was extracted from NP swabs using 
QIAamp Viral RNA Mini Kit (Qiagen, Valencia, CA, USA) according to the 
manufacturer’s protocol and was either used immediately or stored at -80ºC 
until use. The xTAG® Respiratory Viral Panel FAST (Luminex Molecular 
Diagnostics, Toronto) is used to detect and identify multiple respiratory 
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viruses, including influenza A (H1 and H3), influenza B, respiratory syncytial 
virus, coronaviruses (-229E, -OC43, -NL63 and -HKU1), parainfluenza viruses 
(1, 2, 3 and 4), human metapneumovirus, entero-rhinovirus, adenovirus and 
human bocavirus. Human rhinovirus and enteroviruses are closely related 
picornaviruses that cannot be distinguish by xTAG RVP assay, therefore these 
viruses are referred together as entero-rhinovirus throughout this paper. 10μL 
of the viral extract was amplified in a one-step multiplex reverse-transcriptase 
polymerase chain reaction (PCR) to a final volume of 20L containing 4L of 
xTAG 5X OneStep buffer, 1.6L of xTAG OneStep enzyme mix, 1.1L of 
xTAG dNTP mix, 2.0L of xTAG RVP FAST primer mix (containing target-
specific tagged primers and biotin-labeled primers) and 1.3L of xTAG 
RNase-free water. The thermocycling was performed in a Veriti 96 Well 
Thermal Cycler (Applied Biosystems, Foster City, CA, USA) under the 
following cycling conditions: reverse transcription at 50°C for 20 min, Taq 
polymerase activation at 95°C for 15 min followed by 35 cycles at 95°C for 30 
sec, 59°C for 30 sec and 72°C for 30 sec with final extension at 72°C for 2 
min. 2L of the biotinylated, tagged PCR product was hybridized to the bead 
mix containing the anti-tag and detected using the reporter Streptavidin, R-
Phycoerythrin conjugate for 20 min at 45°C.The mean fluorescence intensity 
(MFI) for each bead was generated on the Luminex® LX100/200TM Analyzer 







2.2.3 Statistical analysis 
 
We compared differences in overall clinical presentation between 
influenza and non-influenza acute febrile cases. Clinical parameters like age, 
body temperature were compared using Fisher’s exact test for categorical 
variables and the data sets were compared using two-tailed student t-test to 























3.1 Asymptomatic influenza study 
 
3.1.1 HAI seroconversion  
 
From November 2009 through February 2010, a total of 1482 subjects 
provided paired samples (total of 2964 serum samples) and the demographics 
information of these subjects have been reported previously (Paton et al. 
2011). Antibody levels against influenza A/H1N1 2009 pandemic, seasonal 
influenza A/H3N2 and influenza B on haemagglutination inhibition (HAI) test 
using paired sera from 1482 subjects were measured. Seroconversion is 
determined by at least a four-fold rise in antibody levels at week 12 compared 
to baseline. A total of 65 subjects developed a four-fold or higher rise in 
antibody titers between the baseline and follow-up sample collected at week 
12. Overall, 54 (3.6%) participants seroconverted to influenza A/H1N1 2009, 
6 (0.4%) to influenza A/H3N2 and 6 (0.4%) to influenza B (Table 5). One 
person was infected with influenza A/H1N1 2009 and influenza B as shown 








Table 5 Number of subjects who seroconverted with at least a 4-fold rise in 
antibody titer on HAI for influenza A/H1N1 2009, A/H3N2 or B infection 
between baseline and week 12  
 
Influenza type 
No. of seroconversion1, n (%)a 
(N = 1482) 
Influenza A (H1N1 2009) 54 (3.6) 
Influenza A (H3N2) 6 (0.4) 
Influenza B 6 (0.4) 
Total  65 (4.4)* 
1Seroconversion refer to 4-fold or higher rise in antibody titer in paired sera 
against each influenza subtype. 
aPercentage seroconversion among total number of subjects, N = 1482 
*One person has seroconversion with influenza A/H1N1 2009 and influenza B 
 
3.1.2 PCR on nasal swabs 
 
During the course of 12 weeks, 256 subjects developed flu-like 
symptoms associated with fever, cough and running nose and provided nasal 
swabs. PCR was tested on nasal swabs for influenza A/H1N1 2009, influenza 
A/H3N2 and B. A total of 310 nasal swabs were obtained, with 48 subjects 
provided more swabs than others. Among 256 subjects, 16 tested positive for 
influenza A H1N1 pandemic 2009 (6.3%), 7 positive for seasonal influenza 






Figure 7 Number of nasal swabs positive for influenza A/H1N1 2009, A/H3N2 
and B among subjects who developed influenza-like illness during the course 
of 12 weeks.  
 
3.1.3 Asymptomatic infection 
 
To determine asymptomatic infection, HAI serological results done on 
paired sera was compared with those who provided nasal swabs. Since the 
CHIP trial study protocol required all subjects to provide nasal swabs when 
they experience influenza-like symptoms, this was taken by us as indicative of 
symptomatic infection. Out of the 65 subjects who showed seroconversion on 
HAI for influenza A/H1N1 2009, A/H3N2 or B infection on paired sera, 14 
subjects were symptomatic. 50 subjects (76.9%) had asymptomatic infection, 
with 1 individual having infection to influenza A/H1N1 2009 and influenza B, 





















































54* 11 (20.4) 43 (79.6) 
Influenza A/H3N2 6 2 (33.3) 4 (66.7) 
Influenza B 6* 2 (33.3) 4 (66.7) 
Total 65* 14 (21.5) 50* (76.9) 
1Symptomatic refer to subjects who seroconverted on HAI for influenza and 
provided nasal swabs 
2Asymptomatic refer to subjects who seroconverted on HAI for influenza did 
not provide nasal swabs 
*One person has seroconversion with influenza A/H1N1 2009 and influenza B 
and did not provide nasal swab 
 
Among the total infected cases determined by HAI seroconversion, 
79.6% are asymptomatic for influenza A/H1N1 2009 and 66.7% asymptomatic 
for influenza A/H3N2 and influenza B, figure 8. There is no observed 
significant difference between the asymptomatic rates of the newly emerged 
A/H1N1 2009 and seasonal influenza (A/H3N2 and influenza B) by Fisher’s 





Figure 8 Proportion of asymptomatic infection among different influenza 
subtype 
 
3.1.4 Other respiratory viruses 
 
The nasal swabs were further screened for the presence of other 
respiratory viruses such as rhinovirus, enterovirus, coronavirus, human 
metapneumovirus, parainfluenza 1, 2 and 3, respiratory syncytial virus and 
adenovirus by PCR. Among the 256 subjects, 145 (56.7%) tested positive for at 
least one of the respiratory viruses. As shown in table 7, rhinovirus has the 
highest detection rate (28.5%, 73/256), followed by enterovirus (10.9%, 
23/256), influenza A/H1N1 2009 (6.3%, 16/256), seasonal influenza A/H3N2 
(2.7%, 7/256), influenza B (2.0%, 5/256), human metapneumovirus and 
parainfluenza 1 (1.6%, 4/256), parainfluenza 3 and respiratory syncytial virus 
(1.2%, 3/256), and adenovirus (0.8%, 2/256). No coronavirus and 
parainfluenza 2 were detected and 111 samples (43.3%) were negative for all 













Table 7 Respiratory viruses detected in nasal swabs provided by subjects 
experiencing influenza-like illness during the course of 12 weeks 
 
Respiratory viruses tested 
No. of positives1 (%) 
(N = 256) 
Influenza A/H1N1 2009 16  (6.3) 
Influenza A/H3N2 7 (2.7) 
Influenza B 5 (2.0) 
Rhinovirus 73 (28.5) 
Enterovirus 28 (10.9) 
Human Metapnuemovirus 4 (1.6) 
Parainfluenza 1 4 (1.6) 
Parainfluenza 2 0 (0) 
Parainfluenza 3 3 (1.2) 
Respiratory Syncytial virus 3 (1.2) 
Adenovirus 2 (0.8) 
Coronavirus 0 (0) 
Total  145 (56.7) 
1The no. of positives refer to the number of subjects who provided nasal swab 
samples that are tested positive for each viral agent, relative to the total no. of 
subjects who provided nasal swabs for the study.  
 
Among the positive cases, co-infection of respiratory viruses was 
observed in 24 subjects, with one triple infection (Table 8). Rhinovirus and 
enterovirus, detected in 21 cases, is the most frequently found viral respiratory 











Table 8 Co-infections of respiratory viruses detected in subjects experiencing 
influenza-like illness during the course of 12 weeks 
 
Virus co-infection 
No. of cases  (%) 
(N = 256) 
RV + EV 21 (8.2) 
A/H1N1 2009 + RSV 1 (0.4) 
A/H3N2 + HMPV 1 (0.4) 
A/H3N2 + HMPV + RSV 1 (0.4) 
Total  24 (9.4) 
RV, rhinovirus; EV, enterovirus; A/H1N1 2009, 2009 pandemic influenza A 
H1N1; RSV, respiratory syncytial virus; A/H3N2, seasonal influenza A H3N2; 
HMPV, human metapneumovirus. 
 
3.2 Temporal trends of respiratory viruses in Singapore 
 
3.2.1 Baseline demographic and clinical history 
 
Between January 2008 and December 2012 (5 years), a total of 2100 
adult patients presented with acute febrile illness at selected primary 
healthcare centers were enrolled in this study. The demographic and clinical 
histories of these adult patients are summarized in Table 9. Overall, the 
demographic data and clinical manifestations of those infected with influenza 
A or B were non-specific and similar to those infected with other respiratory 
viruses. Patients with influenza A or B infection were more likely to present 










Table 9 Demographic and clinical presentation in adult patients with acute 
febrile illness, 2008 to 2012 
 
  Virus positive (%)                                 
Virus 
negatived                  
(n = 1338) Characteristics 
Influenzaa               
(n = 500) 
Other Virusesb             
(n = 53) 
Totalc                      
(n = 553) 
Age     
Median 32 41 34 32 
Range 17 - 83 19 - 70 17 - 83 17 - 84 
Ethnicity     
Chinese 253 (50.6) 27 (50.9) 280 (50.6) 678 (50.7) 
Malay 87 (17.4) 13 (24.5) 100 (18.1) 251 (18.8) 
Indian 87 (17.4) 10 (18.9) 97 (17.5) 219 (16.4) 
Others 72 (14.4) 3 (5.7) 75 (13.6) 190 (14.2) 
Gender     
Female 193 (38.6) 24 (45.3) 217 (39.2) 449 (33.6) 
Male 307 (61.4) 29 (54.7) 336 (60.8) 889 (66.4) 
Clinical symptoms     
Fever (≥37.8°C) 447 (89.4)** 39 (73.6) 486 (87.9) 962 (71.9) 
Drowsiness 240 (48) 18 (33.9) 258 (46.7) 579 (43.3) 
Headache 370 (74) 32 (60.4) 402 (72.7) 915 (68.4) 
Backache 116 (23.2) 7 (13.2) 123 (22.2) 339 (25.3) 
Myalgia 312 (62.4) 36 (67.9) 348 (62.9) 852 (63.7) 
Arthralgia 194 (38.8) 15 (28.3) 209 (37.8) 522 (39) 
Loss of appetite 294 (58.8) 32 (60.4) 326 (59) 724 (54.1) 
Abdominal pain 67 (13.4) 5 (9.4) 72 (13) 220 (16.4) 
Diarrhea 24 (4.8) 2 (3.8) 26 (4.7) 95 (7.1) 
Nausea 138 (27.6) 13 (24.5) 151 (27.3) 319 (23.8) 
Vomiting 39 (7.8) 2 (3.8) 41 (7.4) 104 (7.8) 
Red eyes 141 (28.2) 13 (24.5) 154 (27.8) 264 (19.7) 
Rashes 3 (0.6) 0 (0) 3 (0.5) 50 (3.7) 
Retro-orbital 
pain 107 (21.4) 9 (17.0) 116 (21.0) 179 (13.4) 
URTI 457 (91.4) 49 (92.5) 506 (91.5) 941 (70.3) 
aPatients tested positive for Influenza A and B 
bPatients tested positive for either of the respiratory viruses other than Influenza, 
including PIV (1, 2, 3 and 4), RSV, HCoV (229E, OC43, NL63 and HKU1), HMPV, 
HAdV, ERV, HBoV and co-infections. Statistical test was compare between influenza 
and other viruses.  
cPatients tested positive for either of the respiratory viruses 
dPatients tested negative for respiratory viruses 
** represent statistically significant with p value <0.01  






3.2.2 Overall detection of respiratory viruses 
 
Out of the 2100 febrile patients, 209 (10%) were diagnosed as dengue 
and were included in a previously reported study (Low et al. 2011). The 
remaining 1891 dengue-negative patients were thus screened for respiratory 
viruses by direct immunofluorescent assay (DFA) and shell vial isolation. Of 
these, 553 (29.2%) were positive for at least one of the respiratory viruses 
(Table 10) while no etiology was identified for 70.8% of the samples. The 
most common etiology was influenza A virus (19.8%), followed by influenza 
B (6.7%), adenovirus (0.7%), human metapneumovirus (0.6%), parainfluenza 
1 (0.5%), parainfluenza 3 (0.5%), RSV (0.3%) and parainfluenza 2 (0.3%).  
 
 
Table 10 Type of respiratory viruses detected in adult patients with acute 
febrile illness by DFA and virus isolation in shell vials, 2008 – 2012 
 
Virus detected 
No. of positive, n (%) 
N = 1891 
Influenza A 371 (19.8) 
Influenza B 127 (6.7) 
Adenovirus 13 (0.7) 
Human metapneumovirus 12 (0.6) 
Parainfluenza 1 9 (0.5) 
Parainfluenza 2 5 (0.3) 
Parainfluenza 3 9 (0.5) 
Respiratory syncytial virus 5 (0.3) 







3.2.3 Influenza seasonality and subtyping 
 
There are strong seasonal pattern with the detection rate for influenza 
viruses (figure 9). Over the course of 5 years, two peaks could be observed 
annually, with the peak in mid-year (April – June) higher than those at the end 
or beginning of each year (November - February). Seasonal patterns were not 
obvious for the rest of the viruses, possibly due to the smaller number of cases.  
 
Influenza strain typing of the positive cases by PCR indicated a greater 















Figure 9 Monthly activity of influenza A and B from January 2008 to December 2012 in adult patients with acute febrile illness. The 
monthly activity of influenza A and B in each month was plotted over 5 years demonstrating the seasonal trends over the years. Green 












































































































































































































































































































Figure 10 Subtype analysis of Influenza A showed greater proportion of 
H3N2 towards the end of 2010 
 
3.2.4 Detection of respiratory viruses by Luminex xTAG® RVP 
 
While DFA and shell vial isolation were relatively low-cost and 
provided us with a repository of viruses for subsequent analyses, molecular 
diagnostic tools have greater sensitivity for pathogen detection.  We hence 
analyzed a subset of samples collected in 2010 using a commercially available 
multiplex PCR-based kit.  
 
There were a total of 627 NP swabs collected in 2010. 187 were tested 
positive by either by DFA or shell vial isolation and the remaining 440 
respiratory samples that were negative were further analyzed using Luminex 
xTAG® RVP FAST. 66 (10.5%) were tested positive, of which 43 (6.9%) were 










































































































































Influenza A strain typing
H1 H3N2 H1N1 2009
62 
 
OC43, 2 NL63 and 2 HKU1), 7 (1.1%) for influenza A and 1 (0.2%) for 
influenza B, parainfluenza 3 and 4.The results are shown in table 11. Entero-
rhinovirus, human coronaviruses (229E, OC43, NL63 and HKU1) and 
parainfluenza 4 were further detected using xTAG® RVP FAST.  
 
 
Table 11 Type of respiratory viruses detected in adult patients with acute 
febrile illness, by DFA, virus isolation in shell vials and xTAG RVP assay 
 
Detection year 2010 
Virus detected 
No. of positive cases, n (%1) 
N = 627 
DFA and 
Shell vials 
xTAG® RVP Total 
Influenza A 138 (22) 7 (1.1) 145 (23.1) 
Influenza B 37 (5.9) 1 (0.2) 38 (6.1) 
Human Adenovirus 3 (0.5) 0 (0) 3 (0.5) 
Human Metapneumovirus 3 (0.5) 1 (0.2) 4 (0.6) 
Parainfluenza    
Parainfluenza 1 3 (0.5) 0 (0) 3 (0.5) 
Parainfluenza 2 1 (0.2) 0 (0) 1 (0.2) 
Parainfluenza 3 1 (0.2) 1 (0.2) 2 (0.3) 
Parainfluenza 4 NT 1 (0.2) 1 (0.2) 
Respiratory Syncytial Virus 1 (0.2) 0 (0) 1 (0.2) 
Human coronaviruses    
OC43 NT 6 (1.0) 6 (1.0) 
229E NT 2 (0.3) 2 (0.3) 
NL63 NT 2 (0.3) 2 (0.3) 
HKU1 NT 2 (0.3) 2 (0.3) 
Entero-rhinovirus NT 43 (6.9) 43 (6.9) 
Human bocavirus NT 0 (0) 0 (0) 
Total positive 187 (29.8) 66 (10.5) 253 (40.4) 
1Percentage of cases among total dengue negative patients recruited in 2010, n 
= 627 and were tested positive by DFA, virus isolation in shell vials and 
xTAG® RVP FAST assay. NT, not tested;  
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3.2.5 Seasonality of other respiratory viruses 
 
The monthly distribution of the viruses detected by DFA, shell vial 
isolation and Luminex xTAG RVP in 2010 was illustrated in figure 11. 
Consistent with the 5-year data, the prevalence of influenza A was also highest 
in June of 2010.  In contrast, entero-rhinovirus activity appeared highest at both 
the beginning and end of 2010 (figure 11) although this trend is limited only to 
a year’s data. No seasonal pattern was observed for the other viruses possibly 





*Other respiratory viruses detected include parainfluenza viruses (1, 2, 3 and 4), 
respiratory syncytial virus, human coronaviruses (229E, OC43, NL63 and HKU1), 
human metapneumovirus, adenovirus. 
 
Figure 11 Monthly distribution of influenza, entero-rhinovirus and other 



























































































The emergence of virus in humans are often associated with large 
epidemics and the clinical outcome is also likely to be severe.  This is evident 
in the recent epidemics of ebola and Middle East Respiratory Syndrome 
(MERS).  While the spread of these viruses in humans is aided by low or even 
non-existent herd immunity, the outcome of infection is thought to be driven 
by the lack of adaptation.  Indeed, many successful human pathogens, such as 
enteroviruses, cause mostly asymptomatic infection as these viruses have 
adapted to thrive in human hosts over thousands of years of evolution.  These 
adaptations thus lead to minimal host response that thus do not result in any 
significant damage to the host.  Some even go so far as to suggest that this 
may represent a form of symbiotic relationship between viruses and their hosts 
(Bertoletti and Kennedy 2014).  While this notion is interesting, it also 
suggests that the opposite will be true for viruses that jumped from another 
species into humans.  Indeed, seroprevalence studies on SARS coronavirus 
indicated no asymptomatic infection when it emerged in 2003 as a human 
pathogen (Chow et al. 2004, Ho et al. 2004).  While that meant that all who 
were infected with this virus developed disease, it also meant that tracing of 
contacts with cases, placing them in quarantine with daily fever surveillance 
were effective in stemming the spread of this virus in Singapore.   
 
Understanding whether a similar outcome in low asymptomatic rate 
when influenza crosses into humans from another animal species is thus 
important to devise control strategies for future pandemics.  Indeed, all 
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influenza in the 20th century were due to an introduction of new subtype of 
virus from animals to humans.  The 2009 pandemic is the first pandemic in the 
21st century and unlikely to be the last.  This virus crossed from pigs to 
humans.  Results from this thesis shows, through a prospective cohort study, 
that there is a high proportion (79.6%) of asymptomatic infection (table 6) for 
the newly emerged pandemic influenza A H1N1 2009. Such a high proportion 
of asymptomatic infection of the pandemic influenza A H1N1 2009 could 
explain why isolation and quarantine interventions that were essential in 
controlling SARS could not contain the pandemic H1N1 2009.  
 
This is the first prospective cohort study that determined the 
asymptomatic infection rate of influenza. Other studies conducted in 
Singapore that examined seroconversion during the influenza A H1N1 2009 
pandemic reported lower asymptomatic infection rates (Lee et al. 2010 and 
Chen et al. 2010) although these studies focused on specific community in the 
population such as military (Lee et al. 2010) and hospital staff (Chen et al. 
2010). The strengths of the present study include the prospective nature of 
recruiting healthy subjects and following them over 12 weeks to detect for 
asymptomatic influenza infection, the collection of nasal swabs by subjects if 
they experience influenza-like symptoms (fever, runny nose or cough) and the 
online symptom diary as well as the use of paired serum samples for 
serological evidence of infection to influenza. Thus, those subjects who 
seroconverted with 4-fold rise in antibody titres based on haemagglutination 
inhibition (HAI) test to influenza using paired sera but without experiencing 
any influenza-like symptoms during the course of study based on symptoms 
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diary and did not provide nasal swabs are likely true asymptomatic infections. 
This thesis identified 79.6% asymptomatic infection for the pandemic 
influenza A/H1N1 2009 and 66.7% asymptomatic for influenza A/H3N2 and 
influenza B. 
 
Prior to the arrival of the pandemic influenza A H1N1 2009 in 
Singapore, the predominant seasonal influenza that is circulating in Singapore 
was influenza A/H3N2, with very little seasonal influenza A/H1N1 and B 
viruses detected (Tang et al. 2010). This pandemic 2009 virus has rapidly 
replaced the seasonal influenza A/H3N2 to become the predominant strain in 
Singapore within months of its emergence (Leo et al. 2010, Tang et al. 2010). 
This was also demonstrated in the second part of this thesis, figure 10, where 
influenza subtyping of NP swabs collected from adult febrile patients showed 
influenza A H1N1 2009 to be the predominant virus circulating, and a greater 
proportion of A/H3N2 to A/H1N1 2009 in the later part of 2010 with little 
seasonal influenza A H1N1 activity. This could also explain the low number 
of infection with seasonal influenza A/H3N2 and influenza B in this study.  
 
A complication in determining asymptomatic infection is that an 
infected case may show the expected symptoms because of other factors 
unrelated to the infection. In addition, when a case is infected with multiple 
pathogens, it is difficult to distinguish which pathogen is causing the 
symptoms. In this study, there were 3 symptomatic subjects who showed 
seroconversion to influenza but PCR positive for other viral etiology on nasal 
swabs, 2 rhinoviruses (RV) and 1 respiratory syncytial virus (RSV) were 
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detected.  It is not known whether these infections occurred at the same time 
or one after another and it is difficult to differentiate which pathogen caused 
the symptoms. Multiple pathogens can cause similar, non-specific clinical 
presentations that could be easily mis-interpreted clinically. The presence of 
other respiratory viruses on the nasal swabs provided by symptomatic subjects 
also indicated that there were a lot other respiratory viruses other than 
influenza in Singapore in a given limited period (table 7). Without a low-cost 
and rapid point-of-care diagnostic test, working clinical diagnosis and case 
management strategies are guided by information on the prevalence of these 
etiological agents. Furthermore, most of these viral respiratory infections 
mimic those caused by bacteria clinically, and antibiotics are often given to 
treat these infections unnecessarily. Thus, rapid and accurate diagnosis of 
specific respiratory infection not only distinguishes the causative agent but 
also affect patient management since specific anti-viral treatment for 
respiratory virus infection is only available for influenza. The number of 
influenza positives in this study was small, which does not allow for a detailed 
comparison of asymptomatic infection rates between the pandemic and 
seasonal strains. Another limitation is that the subjects that were recruited in 
the CHIP trial might have received vaccination in the previous season against 
seasonal flu that could have some residual immunity to seasonal strains that 
protects against clinical symptoms but not necessarily infection.  
 
For the second part of this thesis, we went on to investigate the 
prevalence of respiratory pathogens in adults patients that presented with acute 
febrile illness in primary healthcare polyclinics in Singapore and the temporal 
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trends of these viruses. Implementation of public health interventions and 
vaccination programs is often guided by the epidemiological data and should 
be tailored to the seasonality of transmission. Our study demonstrates that 
influenza A and B virus as well as entero-rhinovirus were the most common 
etiologies in febrile adult patients presenting at primary healthcare centers in 
Singapore. This pattern is similar to that observed in other adult (Hong et al. 
2004, Minosse et al. 2008, Ren et al. 2009, Yu et al. 2012) but not in pediatric 
populations where respiratory syncytial virus (RSV), parainfluenza, 
adenovirus and rhinovirus predominates (Bezerra et al. 2011, Broor et al. 
2007, Khor et al. 2012, Kwofie et al. 2012). 
  
 In Singapore, we have observed strong seasonal pattern for influenza 
A that peaks twice annually with the peak in mid-year (April – June) higher 
than those at the end or beginning of each year (November - February), similar 
to another report done in Singapore (Chew et al. 1998). This bi-annual 
increase in influenza activity coincided with the winter seasonal epidemics of 
influenza in both northern and southern hemispheres, which suggest that it is 
unlikely that annual seasonal influenza epidemics in the temperate regions are 
seeded from a source population in the tropics at the beginning of winter each 
year, the “source-sink” hypothesis (Bedford et al. 2010, Rambaut et al. 2008, 
Russell et al. 2008), since influenza activities in both regions peaks at around 
the same time. This epidemiological observation supports previously reported 
findings that a complex migration dynamics exist rather than a single source 
population and that no single location acted as global source population for 
influenza outbreak (Bahl et al. 2011). Entero-rhinovirus activity appeared 
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highest at both the beginning and end of 2010. Seasonal patterns were not 
obvious for the rest of the viruses, possibly due to the smaller number of cases.  
 
In temperate regions where there are clearer seasonal pattern for 
influenza epidemic occurring in the winter months, vaccination is carried out 
annually, usually in the autumn season in preparation for the upcoming winter 
where influenza incidence peaks. It is often unclear which recommended 
influenza vaccine composition (the northern or southern hemisphere vaccine 
composition) to use in tropical areas because of the diverse seasonality. 
Therefore influenza vaccination strategy should be tailored according to each 
individual country, based on the local prevalence, timing and seasonality of 
influenza activity and strains, and how they match to the circulating strains in 
the temperate regions. In Singapore yearly influenza vaccination is 
recommended to protect against influenza. Ideally, having a bi-annual 
influenza season suggest that vaccination twice a year before the peak season 
starts would be more effective in preventing influenza in Singapore. However, 
despite the availability of seasonal influenza vaccine in Singapore, the uptake 
in the general population is low, even for healthcare workers and those with 
higher risk of complication (Chor et al. 2011, Tan et al. 2010). Alternatively, 
vaccination for influenza can be done in mid-year where the peak activity 
occurs. The data presented in this study focused on adults. It may be 
worthwhile extending this same study to children. Much of the transmission 




Virus isolation still remains the gold standard in many laboratories and 
together with molecular testing has greatly improved the laboratory’s ability to 
detect viral respiratory infections. Recently identified viruses such as the 
human coronavirus – HKU1, human metapnuemovirus and human bocavirus 
are difficult to isolate using cell culture.  Diagnosis thus relies on molecular 
detection methods. A subset of nasopharyngeal (NP) swabs collected in 2010 
that were negative by shell vial isolation and DFA were further analyzed using 
a commercially available multiplex PCR-based kit, xTAG® RVP FAST. This 
kit is able to detect 7 additional respiratory viruses apart from the 8 viruses 
detected by shell vial isolation and DFA. Entero-rhinovirus, human 
coronaviruses (229E, OC43, NL63 and HKU1) and parainfluenza 4 that could 
not be detected by shell vial isolation and DFA previously were identified 
using xTAG® RVP FAST. Human rhinovirus and enterovirus are closely 
related picornaviruses that cannot be distinguish by xTAG RVP assay. Thus, 
using a combination of virus isolation and molecular techniques can greatly 
improve the detection of respiratory viruses, especially for those that are 













Epidemiological information of newly emerged viruses play a crucial 
role in implementation public health intervention and control measures. The 
findings of this thesis suggest that there was a high proportion of 
asymptomatic infection for the newly emerged pandemic influenza A H1N1 
2009, which could contribute to why isolation and quarantine interventions 
failed to contain the pandemic H1N1 2009.  
 
In Singapore, there is a strong bi-annual seasonal pattern for influenza 
A with the peak in mid-year (April – June) higher than the peak at the end or 
beginning of each year (November - February). Influenza vaccination strategy 
should be tailored according to each individual country, based on the local 
prevalence, timing and seasonality of influenza activity and strains, and how 
they match to the circulating strains in the temperate regions. Ideally, for 
Singapore, vaccination for influenza should be recommended twice a year but 
could also put a strain on those who are at higher risk of infection such as 
healthcare workers with having to vaccinate twice a year. Alternatively, 
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